Delving into the Latest Updates on Semaglutide (Novo Nordisk) with Synapse

RegulationAccelerated Approval (United States), Commissioner's National Priority Voucher (United States), Breakthrough Therapy (China), Priority Review (United States), Conditional marketing approval (Canada)

Login to view timeline

Structure/Sequence

Sequence Code 50953

Source: *****

The rapid emergence of new and highly effective obesity medications has turned the field of pediatric weight management on its head. Adolescents living with obesity, their caregivers, healthcare providers, healthcare systems, policymakers, and payors are now wondering what role health behavior and lifestyle treatment (HBLT) has in terms of body mass index (BMI) reduction, improvements in quality of life and cardiometabolic health, and mitigating nutritional concerns when medications are used. Is intensive (26+ hours) of HBLT needed or could low intensity HBLT be an equally effective alternative; and if so, for whom? Our proposed project will answer these important questions that arise daily in the clinical setting and will generate critical new insights to guide decision-making for teens with obesity and the stakeholders who care deeply about them.

Start Date01 Jan 2027

Sponsor / Collaborator

University of Minnesota

[+2]

NCT07389941

/ Not yet recruitingPhase 4IIT

Semaglutide PrIor to CathEeter Ablation in Patients With Atrial Fibrillation (SPICE-AF)

To evaluate whether pre-treatment with semaglutide is superior to standard care in improving freedom from atrial fibrillation (AF) at 12 months following catheter ablation in patients with obesity and symptomatic AF undergoing first-time ablation.

Start Date01 Oct 2026

Sponsor / Collaborator

Universität zu Lübeck

NCT07021937

/ Not yet recruitingPhase 3IIT

Investigating Brain PLASTICity and GLP-1 Receptor Agonists in the Treatment of Obesity: The PLASTIC Trial

Glucagon-like peptide 1 receptor agonists (GLP-1RA), such as Ozempic and Wegovy, have been rapidly adopted for the treatment of obesity in both youth and adults. However, despite this rapid adoption and the known GLP-1RA mechanism of action for weight loss, which targets brain circuits responsible for appetite and eating behaviors, almost nothing is known about how these drugs affect the brain in youth who are treated for obesity, or how these drugs affect the brain of youth differently from adults. The goal of the current study is to compare youth and adults with obesity who are treated a GLP-1RA and measure potential difference in GLP-1RA associated change in brain function, appetite, and eating behaviors.

Start Date01 May 2026

Sponsor / Collaborator

University of Colorado Denver

[+1]

100 Clinical Results associated with Semaglutide (Novo Nordisk)

Login to view more data

100 Translational Medicine associated with Semaglutide (Novo Nordisk)

Login to view more data

100 Patents (Medical) associated with Semaglutide (Novo Nordisk)

Login to view more data

327

Literatures (Medical) associated with Semaglutide (Novo Nordisk)

01 Feb 2026·JAMA Psychiatry

Semaglutide and Early-Stage Metabolic Abnormalities in Individuals With Schizophrenia Spectrum Disorders

Article

Author: Hartmann, Bolette ; Sass, Marie R. ; Correll, Christoph U. ; Storgaard, Heidi ; Kjaer, Andreas ; Hviid, Malthe ; Schilling, Christoffer ; Oturai, Peter S. ; Gefke, Maria ; Holst, Jens J. ; Vinberg, Maj ; Ekstrøm, Claus T. ; Giver, Malte E. B. ; Zamorski, Alexandra ; Schwarz, Christine R. ; Vilsbøll, Tina ; Rasmussen, Line ; Fink-Jensen, Anders ; Jensen, Andreas ; Klausen, Mette Kruse

Importance:

Individuals with schizophrenia spectrum disorders treated with second-generation antipsychotics (SGAs) are at heightened risk for obesity, prediabetes, and type 2 diabetes, contributing to increased cardiovascular morbidity and premature mortality. Early intervention with glucagon-like peptide–1 receptor agonists (GLP-1RAs) may help mitigate long-term cardiometabolic risk.

Objective:

To evaluate the efficacy of adjunctive semaglutide on glycemic control, weight-associated outcomes, and cardiometabolic risk factors in individuals with schizophrenia spectrum disorders receiving clozapine or olanzapine and exhibiting early glycemic abnormalities.

Design, Setting, and Participants:

This was a multicenter, double-blind, placebo-controlled, randomized clinical trial. Participants were enrolled from 3 clinical sites in Denmark between September 2021 and August 2024. Screening individuals were aged 18 to 65 years with schizophrenia spectrum disorders and clozapine or olanzapine treatment initiated within the past 5 years. Participants had early-stage glycemic dysregulation (hemoglobin A 1c [HbA 1c ], 5.4%-7.4%) and were not receiving antidiabetic therapy.

Interventions:

Participants received once-weekly subcutaneous semaglutide (1 mg) or a matching placebo, administered adjunctively to SGA therapy for 26 weeks.

Main Outcomes and Measures:

The prespecified primary outcome was change in HbA 1c level from baseline to week 26. The primary analysis adhered to the intention-to-treat principle.

Results:

Of 104 individuals screened, 73 were randomized and 57 (78%) completed the trial. Baseline characteristics were comparable between groups. Mean (SD) age was 35 (12) years, 48 were female (65%), and mean (SD) body mass index was 36.1 (7.9). At week 26, semaglutide significantly reduced HbA 1c level compared with placebo (mean difference, −0.25%; 95% CI, −0.33 to −0.16; P &lt; .001); 43% of participants (12 of 28) treated with semaglutide achieved low-risk HbA 1c levels (&lt;5.4%) vs 3% with placebo. Greater reductions in body weight (−9.2 kg; 95% CI, −13.3 to −5.1 kg; P &lt; .001), waist circumference (−7.0 cm; 95% CI, −10.6 to −3.3 cm; P &lt; .001), and fat mass (−6.1 kg; 95% CI, −10.2 to −1.9 kg; P = .006) were observed with semaglutide. No differences in lipid levels, liver function, blood pressure, or psychiatric symptoms were observed. Gastrointestinal adverse events were common but mild and transient; psychiatric adverse events were similar across groups.

Conclusions and Relevance:

Results of this randomized clinical trial show that adjunctive semaglutide significantly improved glycemic control and weight outcomes in individuals with schizophrenia spectrum disorders. Secondary outcomes were exploratory. These findings support the use of GLP-1RAs as a potential early intervention strategy to reduce cardiometabolic risk in this vulnerable population.

Trial Registration:

ClinicalTrials.gov Identifier: NCT04892199

01 Jan 2026·Journal of Cosmetic Dermatology

Rising Public Interest in Weight Loss Medications and Growing Awareness of Their Aesthetic Sequelae: An Infodemiologic Google Trends Analysis and Clinical Diagnostic Patterning

Article

Author: Linneman‐Heath, Jacob ; Sajic, Dusan ; McCarthy, Alec D. ; Durkin, Alan ; Dacso, Mara ; Durairaj, Kay

ABSTRACT:

Background:

Glucagon‐like peptide‐1 receptor agonists (GLP‐1 RAs) have gained rapid popularity for both medical and consumer‐directed weight loss. This growth has been accompanied by increased public discussion regarding facial aesthetic changes, commonly referred to as “Ozempic face,” characterized by volume depletion and cutaneous laxity.

Objective:

To quantify temporal patterns of public search interest in a widely known GLP‐1 RA and evaluate corresponding awareness of its cosmetic facial sequelae using infodemiologic methods.

Methods:

Google Trends data for “Ozempic” and related frequently co‐searched queries were analyzed from November 2021 to December 2024. Trends in relative search volume (RSV) were examined, with particular focus on terms associated with facial aesthetics, including “Ozempic face” and “plastic surgeons Ozempic face.”

Results:

RSV for “Ozempic” showed a steady upward trajectory over the study period. Queries related to facial aesthetic consequences exhibited substantial proportional increases. Notably, “Ozempic face” demonstrated a 4600% rise in RSV, and searches for “plastic surgeons Ozempic face” similarly grew markedly.

Conclusions:

Public interest in GLP‐1 RAs is strongly associated with rising awareness and concern about their facial aesthetic effects. These trends suggest that aesthetic practitioners should expect more patient inquiries regarding GLP‐1–related facial changes and should proactively integrate counseling and corrective treatment options into clinical practice.

01 Jan 2026·KIDNEY INTERNATIONAL

REMODELing mechanistic trials for kidney disease: a multimodal, tissue-centered approach to understand the renal mechanism of action of semaglutide

Article

Author: Belmar, Nicolas ; Pruijm, Menno ; Cherney, David Z I ; Schytz, Philip A ; Kretzler, Matthias ; Bjornstad, Petter ; Tuttle, Katherine R ; Gunnarsson, Thomas ; Hodgin, Jeffrey B ; Das, Vivek

Chronic kidney disease poses a major global health burden and is one of the most common complications of type 2 diabetes. Drug trials have demonstrated that treatments, including sodium-glucose cotransporter-2 inhibitors, a glucagon-like peptide-1 receptor agonist, and a nonsteroidal mineralocorticoid receptor antagonist, mitigate chronic kidney disease progression, but the underlying nephroprotective mechanisms of action remain incompletely understood, partly ascribed to their pleiotropic actions. New innovative trial designs are needed to tackle simultaneously the hemodynamic and structural effects induced by these drugs. The REMODEL trial (REnal MODE of action of semagLutide in patients with type 2 diabetes and chronic kidney disease; ClinicalTrials.gov identifier: NCT04865770) is designed to explore the mechanisms of action of semaglutide with a novel multiparametric approach, integrating functional magnetic resonance imaging and research kidney biopsies for structural and molecular interrogation and blood and urine biomarker analysis. Better understanding of these mechanisms will help explain semaglutide's beneficial effects on kidney disease outcomes, reported in the FLOW (Evaluate Renal Function with Semaglutide Once Weekly; ClinicalTrials.gov identifier: NCT03819153) trial, and may identify patient subpopulations to optimize treatment strategies. By combining diverse and state-of-the-art methods, REMODEL aims to pave the way to a larger use of mechanism of action trials in the near future. To this purpose, this article describes the REMODEL framework, methods, technical challenges, and lessons learned as a platform for future mechanistic trials of chronic kidney disease therapies and beyond.

2,666

News (Medical) associated with Semaglutide (Novo Nordisk)

10 Feb 2026

·www.prnewswire.com

Nation's Largest Thyroid Cancer Center Publishes White Paper Finding No Convincing Evidence That GLP-1 Medications Cause Common Thyroid Cancers

Comprehensive review aims to clarify growing public concern around Ozempic®, Wegovy®, and Mounjaro® TAMPA, Fla., Feb. 10, 2026 /PRNewswire/ -- With the rapid rise in use of GLP-1 receptor agonist medications such as Ozempic®, Wegovy®, and Mounjaro® for diabetes and weight loss, public concern has grown over a possible link to thyroid cancer. A newly released white paper from the Clayman Thyroid Center offers a comprehensive review of the scientific evidence and concludes that the best available human data do not show these medications cause (or have any effect upon) the most common types of thyroid cancer. The white paper, titled "Do GLP-1 Weight-Loss Shots Like Ozempic and Mounjaro Really Raise Thyroid Cancer Risk? The Latest Facts Explained," examines mechanistic research, clinical trials, large population studies, and real-world clinical experience. Its central message: much of the current fear is driven by misunderstanding rather than strong human evidence. "Thyroid cancer is not a single disease, and that distinction matters," said Gary L. Clayman, MD, FACS, FACE, senior author of the white paper and an extremely high-volume thyroid cancer surgeon. "The FDA boxed warning tied to GLP-1 medications is specific to a rare cancer called medullary thyroid carcinoma. It does not apply to the common thyroid cancers that account for more than 95 percent of cases." The FDA warning originated from rodent studies in which animals developed C-cell tumors when exposed to GLP-1 drugs. However, important biological differences exist between rodents and humans, and large human studies have not demonstrated a similar pattern. According to the Clayman Thyroid Center's review, major international cohort studies and meta-analyses have not found increased thyroid cancer rates among GLP-1 users. Some studies showing possible "associations" may be explained by detection bias. Patients on GLP-1 therapy often have more medical visits, imaging, and specialist care, which can increase the likelihood of discovering pre-existing thyroid nodules or small cancers that might otherwise remain undetected. "When diagnoses rise shortly after starting a medication, that pattern often reflects finding something that was already there," said Rashmi Roy, MD, FACS, co-author of the white paper. "That is very different from a drug actually causing a new cancer." The review emphasizes that for patients with papillary, follicular, or Oncocytic (Hürthle cell) thyroid cancers, current evidence does not support the idea that GLP-1 medications cause these diseases or worsen their course. For these individuals, decisions about GLP-1 therapy should be individualized, considering metabolic benefits and overall health goals. However, the authors stress that caution remains appropriate for a small, specific group. GLP-1 receptor agonists are contraindicated in patients with a personal or family history of medullary thyroid carcinoma or in those with Multiple Endocrine Neoplasia type 2 (MEN2), consistent with existing FDA labeling. The Clayman Thyroid Center treats approximately 2,000 thyroid cancer patients each year and is among the highest-volume thyroid centers in the world. Within this large clinical practice, surgeons have not observed a pattern linking GLP-1 use to medullary thyroid carcinoma. "In a practice that sees more thyroid cancer than almost anywhere globally, we are not seeing a surge of medullary thyroid cancer linked to these medications," Dr. Clayman said. The authors also caution that oversimplified headlines and social media summaries can blur important distinctions between cancer subtypes and exaggerate risk. Such confusion can lead patients to discontinue beneficial medications or experience unnecessary anxiety. "Patients deserve clear, evidence-based guidance," Dr. Roy said. "Our goal is to provide clarity so people can make informed decisions with their physicians." The full white paper is available through the Clayman Thyroid Center's website and is intended as a resource for clinicians, patients, and media navigating this complex topic. About the Clayman Thyroid Center Founded by one of the nation's best-known thyroid surgeons, the Clayman Thyroid Center is the highest volume thyroid cancer referral center in the United States. The Center boasts the most experienced thyroid surgeons in the US who provide personalized care allowing the greatest opportunity for cancer cure, wellness, and cosmetic, and functional, outcomes via all types of thyroid surgery from minimal incision to scarless thyroid surgery to advanced cancer care. | (813) 940-3130 SOURCE Clayman Thyroid Center 21% more press release views with Request a Demo

10 Feb 2026

·www.biospace.com

Hims & Hers’ Woes Compound as FDA Hits Company With Warning Letter

iStock, Lemon_tm The agency flagged several violations at a compounding pharmacy owned by Hims & Hers, including “infestation by rodents, birds insects, and other vermin.” In a warning letter issued in June last year to MedisourceRx, a compounding pharmacy owned by Hims & Hers, the FDA cited clear violations of good manufacturing practices. The revelations, first reported Monday by STAT News , add to the troubles of the telehealth company, which has come under fire from both regulators and Novo Nordisk for selling compounded semaglutide. An FDA inspector found that facilities for drug manufacturing, processing, packaging or storage “are not free of infestation by rodents, birds insects [sic], and other vermin,” according to the warning letter . The inspector also spotted a live spider in the area where MedisourceRx produced active pharmaceutical ingredients for human drugs. Among these products, the warning letter specified, was Hims & Hers’ compounded semaglutide injection. The FDA also flagged a dead cricket which “was observed in the middle of the incubator room.” MedisourceRx uses these incubators for fill vials as part of the manufacturing of drugs for human use. Aside from the infestation, the FDA inspector also noted that one patient who had taken a dose of injectable compounded semaglutide experienced severe gastrointestinal issues that necessitated “three nights of hospital stay.” MedisourceRx “has not submitted an adverse event report” as required, the letter claimed. “Patient safety and regulatory compliance are foundational to how we operate,” a spokesperson for Hims & Hers told STAT News, which reported that the FDA sent a second letter to MedisourceRx in December 2025, which has yet to be released publicly. The spokesperson also told STAT that the company is working on addressing the FDA’s concerns about reporting of toxicities, but insisted that the issues of infestation enumerated in the June letter no longer appear in the December communique. The spokesperson did not provide STAT a copy of this latter letter. The last few days have been rough for Hims. The company last week launched a compounded version of oral semaglutide, triggering a firestorm of backlash from regulatory authorities and Novo Nordisk. FDA Commissioner Marty Makary said in an X post that the agency will “take swift action against companies mass-marketing illegal copycat drugs.” Mike Stuart, general counsel for the Department of Health and Human Services, also blasted Hims’ knockoff pill, saying in a Feb. 7 X post that he has referred the matter “to the Department of Justice for investigation.” Novo has also sued Hims for allegedly infringing on key patents protecting semaglutide. John Kuckelman, the pharma’s general counsel, said that the company could seek trebled damages that could reach “hundreds of millions” of dollars.

Patent Infringement

10 Feb 2026

·pmlive.com

Novo Nordisk announces positive results for CagriSema in type 2 diabetes

Novo Nordisk has announced positive headline results from its trial of CagriSema (cagrilintide and semaglutide) in weight loss and blood glucose control. Data from the phase 3 REIMAGINE 2 trial, part of the global REIMAGINE programme of clinical trials, showed that the weight loss and blood glucose control demonstrated by CagriSema at 68 weeks was superior to those offered by semaglutide. These results were consistent across all tested doses. The trial evaluated 2,728 people living with type 2 diabetes who were inadequately controlled with metformin with or without an SGLT2 inhibitor. Around 40% of participants were treated with an SGLT2 inhibitor prior to trial initiation. Those with a baseline body weight of 101kg lost an average of 14.2% after 68 weeks while using, with no weight loss plateau observed at week 68. This is compared to a weight loss of 10.2% for those using semaglutide 2.4mg. In addition, blood glucose control improved by 1.9%, from a baseline of 8.2%, after 68 weeks for those using CagriSema 2.4mg, compared to 1.76% for those using semaglutide 2.4mg. CagriSema demonstrated a favourable tolerability and safety profile in the trial, with the most common adverse events being gastrointestinal and the majority of these being mild to moderate in severity. CagriSema combines the long-acting amylin receptor agonist cagrilintide and the long-acting GLP-1 receptor agonist semaglutide. Complete results from REIMAGINE 2 will be presented at a scientific conference later in 2026. Following results from the REIMAGINE programme, Novo Nordisk plans to begin regulatory activities regarding CagriSema in type 2 diabetes. CagriSema was previously submitted to the US FDA in December 2025. Martin Holst Lange, executive vice president, chief scientific officer and head of R&D at Novo Nordisk, said: “By combining semaglutide and cagrilintide, we’re seeing superior outcomes in both blood glucose control and weight reduction beyond those achieved with each therapy individually. “The results strengthen our belief that CagriSema could be the first amylin-based combination therapy and a promising treatment option for individuals with type 2 diabetes, that also has a focus on weight loss.”

Clinical ResultPhase 3

100 Deals associated with Semaglutide (Novo Nordisk)

Login to view more data

External Link

KEGG	Wiki	ATC	Drug Bank
D10025	Semaglutide (Novo Nordisk)	A10BJ06	DB13928

R&D Status

Approved

10 top approved records.

Login

to view more data

Indication	Country/Location	Organization	Date
Fibrosis, Liver	United States	Novo Nordisk, Inc.	22 Dec 2025
Pulmonary Fibrosis	Canada	Novo Nordisk Canada, Inc.	21 Dec 2025
Cardiovascular Diseases	United States	Novo Nordisk, Inc.	15 Aug 2025
Metabolic Dysfunction Associated Steatohepatitis	United States	Novo Nordisk A/S	15 Aug 2025
Metabolic Dysfunction Associated Steatohepatitis	United States	Novo Nordisk, Inc.	15 Aug 2025
Chronic Kidney Diseases	United States	Novo Nordisk, Inc.	28 Jan 2025
Chronic Kidney Diseases	United States	Novo Nordisk A/S	28 Jan 2025
Stroke	Australia	Novo Nordisk Pharmaceuticals Pty Ltd.	16 Dec 2024
Myocardial Infarction	Canada	Novo Nordisk Canada, Inc.	27 Nov 2024
Obesity	United States	Novo Nordisk, Inc.	04 Jun 2021
Overweight	United States	Novo Nordisk, Inc.	04 Jun 2021
Diabetes Mellitus, Type 2	United States	Novo Nordisk, Inc.	05 Dec 2017

Developing

10 top R&D records.

Login

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
Albuminuria	Phase 3	Canada	Novo Nordisk A/S	14 Mar 2022
Albuminuria	Phase 3	Germany	Novo Nordisk A/S	14 Mar 2022
Albuminuria	Phase 3	Netherlands	Novo Nordisk A/S	14 Mar 2022
Albuminuria	Phase 3	Spain	Novo Nordisk A/S	14 Mar 2022
Osteoarthritis, Knee	Phase 3	United States	Novo Nordisk A/S	01 Oct 2021
Osteoarthritis, Knee	Phase 3	Canada	Novo Nordisk A/S	01 Oct 2021
Osteoarthritis, Knee	Phase 3	Colombia	Novo Nordisk A/S	01 Oct 2021
Osteoarthritis, Knee	Phase 3	Denmark	Novo Nordisk A/S	01 Oct 2021
Osteoarthritis, Knee	Phase 3	France	Novo Nordisk A/S	01 Oct 2021
Osteoarthritis, Knee	Phase 3	Norway	Novo Nordisk A/S	01 Oct 2021

Login to view more data

Clinical Result

Indication

Phase

Evaluation

View All Results

Study	Phase	Population	Analyzed Enrollment	Group	Results	Evaluation	Publication Date


NCT04779697 (CTgov)	Phase 1	Obesity	96	GLP-1 analogue - semaglutide (GLP-1a)	gkqyupduix(xhqpjhivhx) = axcjqionaz gtghofxaqc (xhxmnnzqvm, 0.6) View more	-	10 Feb 2026
				Placebo (Placebo)	gkqyupduix(xhqpjhivhx) = ydrhmtvfwe gtghofxaqc (xhxmnnzqvm, 0.4) View more
NCT05788965 (CTgov)	Phase 2/3	Cystic Fibrosis \| Obesity \| Cystic fibrosis related diabetes	8	Semaglutide	vubqlwccmk(qbmjjvwanr) = urwgkmozuz okubpvybvl (valgokoauz, 1.9) View more	-	21 Jan 2026
NCT05579249 (CTgov)	Phase 4	Obesity	500	Semaglutide (Semaglutide 2.4 mg)	eafrvfrizf = xdptfclqjy slkzaflsky (kdssjdqzuw, boynbboqex - jtcbxuiamq) View more	-	14 Jan 2026
				bupropion+naltrexone+orlistat+phentermine+topiramate+liraglutide (Other Anti-obesity Medications (AOMs))	eafrvfrizf = wyavjerqnz slkzaflsky (kdssjdqzuw, dbgzjrjcro - euwddxohln) View more
NCT04865770 (REMODEL, CTgov)	Phase 3	Diabetes Mellitus, Type 2 \| Chronic Kidney Diseases	106	Semaglutide (Semaglutide 1.0 mg)	fabhjvqlhe(hlkdbmpbrh) = adgabdbuvg hvwwqeqlyy (xdjzgwfuvu, 5.35) View more	-	14 Jan 2026
				placebo+semaglutide (Placebo)	fabhjvqlhe(hlkdbmpbrh) = ojfrpaozkq hvwwqeqlyy (xdjzgwfuvu, 7.39) View more
NCT04969939 (CTgov)	Phase 2	Obesity	120	Semaglutide+NNC0165-1875 (Part 1: NNC0165-1875 1.0 mg + Semaglutide 2.4 mg)	qgcphdmdfg = dilchmibla plzmxnvgav (deyizuouxl, tpsjvjfiky - lrcvdewnqp) View more	-	08 Jan 2026
				Semaglutide+NNC0165-1875 (Part 1: NNC0165-1875 2.0 mg + Semaglutide 2.4 mg)	qgcphdmdfg = fgviwcldrd plzmxnvgav (deyizuouxl, cacgyllttr - lxugsmwsyi) View more
NCT04865770 \| NCT03819153 (REMODEL, Pubmed \| Kidney Int)	Phase 2	Kidney Diseases	50	Semaglutide (Type 2 Diabetes + Chronic Kidney Disease)	opvyojftpw(ysdyuwpbem) = xavnfckcny ctpmyaktut (itgygrdqmu )	Positive	01 Jan 2026
NCT03574597 (SELECT, Pubmed \| J Med Econ)	Phase 3	Cardiovascular Diseases \| Obesity	-	Semaglutide 2.4 mg	ruoqmxeegn(xooqkevywq) = mrbcmefywp mobcagkpve (xdozxqkfvc ) View more	Positive	31 Dec 2025
NCT03574597 (SELECT, Pubmed \| JAMA Cardiol)	Phase 3	Cardiovascular Diseases \| Obesity	17,604	Semaglutide 2.4 mg	pxcirqiaiz(mqkvclbsku) = quqjogsljr fxfkfjryvh (iialbpqwsm ) View more	Positive	23 Dec 2025
				Placebo	pxcirqiaiz(mqkvclbsku) = cbnalcdpdk fxfkfjryvh (iialbpqwsm ) View more
NCT04892199 (Pubmed \| JAMA Psychiatry)	Phase 2	Schizophrenia	73	Semaglutide 1 mg	qifdflfdte(gfavqtjplq) = kbmmpwhzzs mbvbfmbmfi (zgmnwujagf )	Positive	03 Dec 2025
NCT04971785 (WAYFIND, CTgov)	Phase 2	Metabolic Dysfunction Associated Steatohepatitis \| Fibrosis \| Compensated cirrhosis	457	Semaglutide (SEMA)+Cilofexor (CILO)/Firsocostat (FIR) (SEMA + CILO/FIR FDC)	braerzpowk = vdinknbzmi bwwwqqsewv (jpqzyendxp, mynmjsojon - tapothpjln) View more	-	26 Nov 2025
				PTM SEMA+PTM CILO/FIR (PTM SEMA + PTM CILO/FIR)	braerzpowk = ldbvmljqsb bwwwqqsewv (jpqzyendxp, ndetrrawgn - ghjnezjvzv) View more

Login to view more data

Translational Medicine

Boost your research with our translational medicine data.

login

or

view full example data

Boost your research with our translational medicine data.

Deal

Boost your decision using our deal data.

login

or

view full example data

Boost your decision using our deal data.

Core Patent

Boost your research with our Core Patent data.

login

or

view full example data

Boost your research with our Core Patent data.

Clinical Trial

Identify the latest clinical trials across global registries.

login

or

view full example data

Identify the latest clinical trials across global registries.

Approval

Accelerate your research with the latest regulatory approval information.

login

or

view full example data

Accelerate your research with the latest regulatory approval information.

Biosimilar

Competitive landscape of biosimilars in different countries/locations. Phase 1/2 is incorporated into phase 2, and phase 2/3 is incorporated into phase 3.

login

or

view full example data

Competitive landscape of biosimilars in different countries/locations. Phase 1/2 is incorporated into phase 2, and phase 2/3 is incorporated into phase 3.

Regulation

Understand key drug designations in just a few clicks with Synapse.

login

or

view full example data

Understand key drug designations in just a few clicks with Synapse.

Semaglutide (Novo Nordisk)

Overview

Basic Info

Structure/Sequence

Related

External Link

R&D Status

Clinical Result

Translational Medicine

Deal

Core Patent

Clinical Trial

Approval

Biosimilar

Regulation